Treprostinil derivative compounds and methods of using same
Compounds represented by formulae I, II, III, and IV including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable treatment dosage. Transdermal applications can be used.
1. A compound according to Formula (IA)
wherein,
Z is —OH, —OR 11 , or P 1 ;
R 11 is alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, haloalkyl, heteroalkyl, substituted heteroalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, alkylcycloalkyl, substituted alkylcycloalkyl, alkylcycloheteroalkyl, or substituted alkylcycloheteroalkyl,
P 1 is selected from the group consisting of:
wherein,
m is 1, 2, 3, or 4;
R 14 and R 15 are independently in each occurrence selected from the group consisting of H, cycloalkyl, alkylcycloalkyl, haloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, substituted aryl, substituted heteroaryl, substituted arylalkyl, and substituted heteroarylalkyl; or
R 14 and R 15 taken together with the atoms to which they attach optionally form a 5- to 7-membered ring; and,
R 1 and R 2 are independently H or P 2 , wherein at least one of R 1 and R 2 is P 2 , wherein
P 2 is selected from the group consisting of:
wherein,
R 14 is selected from the group consisting of H, cycloalkyl, alkylcycloalkyl, haloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, substituted aryl, substituted heteroaryl, substituted arylalkyl, and substituted heteroarylalkyl;
or an enantiomer or a pharmaceutically acceptable salt thereof.
2. A composition comprising at least one compound according to claim 1 and at least one other component.
3. A composition according to claim 2 formulated for transdermal delivery.
4. A composition according to claim 2 formulated for transdermal delivery with a patch.
5. A composition according to claim 2 , further comprising at least one solvent.
6. A method of treating pulmonary hypertension, comprising administering to a subject in need of treatment a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.
7. The method of claim 6 , wherein the pulmonary hypertension is pulmonary arterial hypertension.
8. The method of claim 6 , wherein the compound is administered transdermally.
9. The method of claim 8 , wherein the compound is administered via a transdermal patch.